Cancer Gene Therapy
| Discipline | Oncology, gene therapy, cell therapy |
|---|---|
| Language | English |
| Edited by | Leandro Castellano |
| Publication details | |
| History | 1994–present |
| Publisher | Nature Portfolio (United Kingdom) |
| Frequency | Monthly |
| Hybrid | |
| 6.4 (2025) | |
| Standard abbreviations | |
| ISO 4 | Cancer Gene Ther. |
| Indexing | |
| ISSN | 0929-1903 (print) 1476-5500 (web) |
| Links | |
Cancer Gene Therapy is a monthly peer-reviewed medical journal covering the use of gene therapy and cell therapy in cancer research and treatment. It is published by Nature Portfolio and was established in 1994. The editor-in-chief is Leandro Castellano.[1]
The journal publishes laboratory and clinical research papers, review articles, brief communications, case reports, industry perspectives, and letters. Its scope includes gene-transfer technologies, viral and non-viral delivery systems, RNA interference, cancer vaccines, tumor immunology, immunotherapy, cellular therapies, cancer stem cells, tumor-suppressor genes, drug resistance, apoptosis, and DNA synthesis and repair.[2]
Abstracting and indexing
[edit source]The journal is abstracted and indexed in:[3]
- BIOSIS Previews
- MEDLINE(United States National Library of Medicine)
- Pharma Collection (ProQuest)
- Science Citation Index
- Science Citation Index Expanded
- Scopus
According to the Journal Citation Reports, the journal has a 2025 impact factor of 6.4.[4]
References
[edit source]- ↑ "Cancer Gene Therapy". Nature. Springer Nature. Retrieved 20 July 2026.
- ↑ "Journal Information". Cancer Gene Therapy. Springer Nature. Retrieved 20 July 2026.
- ↑ "Cancer Gene Therapy". MIAR: Information Matrix for the Analysis of Journals. University of Barcelona. Retrieved 2026-07-20.
- ↑ "Antibodies". 2025 Journal Citation Reports (Science ed.). Clarivate. 2026 – via Web of Science.